Journal of Medicinal Chemistry · 2002 · 70 citations · 10 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignEnzymologyStructure-activity RelationshipsBioinorganic ChemistryEnzyme FunctionEnzyme InhibitionEnzyme KineticsIron Chelation TherapyStructure-activity Relationship Analysis5-Lipoxygenase InhibitionEnzyme ActivityEnzyme Activity RegulationMetalloenzyme DiscoveryMetalloenzyme MechanismsMetalloenzyme Structure
A range of novel 3-hydroxypyridin-4-ones with different R(2) substitutents has been synthesized for the investigation of the structure-activity relationship between the chemical nature of the ligand and the inhibitory activity of the iron-containing metalloenzyme 5-lipoxygenase. Results indicate that the molecular dimensions, together with the lipophilicity, have a critical impact on the ability of this class of chelator to inhibit 5-lipoxygenase. Hydrophilic ligands with a bulky R(2) substitutent tend to be weak inhibitors; thus 1,6-dimethyl-2-(4'-N-n-propylsuccinamido)methyl-3-hydroxypyridin-4(1H)-one (22b) which has the largest R(2) substitutent only caused 2% inhibition of the enzyme activity after 30 min incubation at 110 microM IBE (iron-binding equivalents), as compared with deferiprone which caused 40% inhibition of the enzyme activity, under the same conditions.
10
The development of iron chelators for clinical use
Alain Ghio, Alvin L. Crumbliss · Free Radical Biology and Medicine · 1995 · 234 citations
Medicine, Hematology, Pharmacology +13
Paul S. Dobbin, Robert C. Hider, Adrian D. Hall et al. · Journal of Medicinal Chemistry · 1993 · 215 citations
Hematology: Basic Principles and Practice
Charles W. Chesterman · Pathology · 1992 · 147 citations
Beverley L. Ellis, Robert C. Hider, M. Bilayet Hossain et al. · Journal of Medicinal Chemistry · 1996 · 86 citations